PMID: 9632404Jun 19, 1998Paper

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group

BMJ : British Medical Journal
K MichaëlssonS Ljunghall

Abstract

To determine the relative risk of hip fracture associated with postmenopausal hormone replacement therapy including the effect of duration and recency of treatment, the addition of progestins, route of administration, and dose. Population based case-control study. Six counties in Sweden. 1327 women aged 50-81 years with hip fracture and 3262 randomly selected controls. Use of hormone replacement therapy. Compared with women who had never used hormone replacement therapy, current users had an odds ratio of 0.35 (95 % confidence interval 0.24 to 0.53) for hip fracture and former users had an odds ratio of 0.76 (0.57 to 1.01). For every year of therapy, the overall risk decreased by 6% (3% to 9%): 4% (1% to 8%) for regimens without progestin and 11% (6% to 16%) for those with progestin. Last use between one and five years previously, with a duration of use more than five years, was associated with an odds ratio of 0.27 (0.08 to 0.94). After five years without hormone replacement therapy the protective effect was substantially diminished (-7% to 48%). With current use, an initiation of therapy nine or more years after the menopause gave equally strong reduction in risk for hip fracture as an earlier start. Oestrogen treatment with ...Continue Reading

References

Dec 15, 1992·Annals of Internal Medicine·D GradyS R Cummings
Nov 7, 1992·BMJ : British Medical Journal·J A KanisL Miravet
Jul 1, 1992·Annals of Internal Medicine·E G LufkinB L Riggs
Feb 1, 1992·Journal of Internal Medicine·R P Heaney
Feb 1, 1991·The American Journal of Medicine·J C GallagherD Goldgar
Jan 1, 1991·Calcified Tissue International·T C Hillard, J C Stevenson
Oct 1, 1990·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C Christiansen, R Lindsay
May 1, 1990·Endocrine Reviews·J C Prior
Jun 26, 1986·The New England Journal of Medicine·B L Riggs, L J Melton
Oct 1, 1987·The Journal of Clinical Endocrinology and Metabolism·L Nilas, C Christiansen
Nov 5, 1987·The New England Journal of Medicine·D P KielM A Moskowitz
Jun 1, 1984·Obstetrics and Gynecology·R LindsayD M Clark
Dec 8, 1983·The New England Journal of Medicine·A HorsmanC Nordin
Nov 20, 1980·The New England Journal of Medicine·N S WeissJ R Daling
Jan 1, 1995·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·P MaximG M Spitalny
Oct 14, 1993·The New England Journal of Medicine·D T FelsonJ J Anderson
Dec 1, 1996·Obstetrics and Gynecology·M L HammarM K Niklasson
Feb 19, 1997·JAMA : the Journal of the American Medical Association·D L SchneiderD J Morton
Aug 1, 1997·American Journal of Obstetrics and Gynecology·T NaessenH C Larsen

❮ Previous
Next ❯

Citations

Jun 9, 2004·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·Helen M MacdonaldDavid M Reid
Jan 27, 2005·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J A KanisB Jönsson
Jun 8, 2006·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·H HallströmK Michaëlsson
May 12, 2007·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·U SennerbyK Michaëlsson
Nov 7, 2007·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C M LofthusJ A Falch
Jan 17, 2012·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·R O StøenC M Lofthus
Jan 9, 2004·Fertility and Sterility·UNKNOWN Practice Committee of the Americal Society for Reproductive Medicine
Sep 15, 2004·Fertility and Sterility·UNKNOWN Practice Committee of the American Society for Reproductive Medicine
Aug 17, 2001·Obstetrics and Gynecology·B EttingerA Van Gessel
May 8, 1999·Lancet·K MichaëlssonS Ljunghall
Jun 1, 2001·European Journal of Obstetrics, Gynecology, and Reproductive Biology·S Rozenberg, H Ham
Jul 5, 2001·Neuroscience Letters·C L DarlingtonP F Smith
Dec 22, 1999·Maturitas·T VihtamäkiR Tuimala
Mar 19, 2004·The New England Journal of Medicine·Henry G BoneUNKNOWN Alendronate Phase III Osteoporosis Treatment Study Group
Feb 4, 2006·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Sarianna SipiläTaina Rantanen
Oct 16, 2001·Clinical Obstetrics and Gynecology·M Taylor
Sep 16, 1999·Menopause : the Journal of the North American Menopause Society·M D Scheiber, R W Rebar
Jan 25, 2003·Menopause : the Journal of the North American Menopause Society·Saranya WattanakumtornkulDaniel B Williams
Jul 14, 2006·Menopause : the Journal of the North American Menopause Society·Toshiyuki YasuiMinoru Irahara
Jan 26, 2006·Obstetrical & Gynecological Survey·James A SimonAntonio Lombardi
Aug 7, 2010·Menopause : the Journal of the North American Menopause Society·Eva L RibomTord Naessen
May 1, 1999·BMJ : British Medical Journal·R Eastell
Oct 6, 2001·BMJ : British Medical Journal·T J Wilkin, D Devendra
Jun 11, 2011·BMC Public Health·Jonas F LudvigssonPetra Otterblad Olausson
Oct 4, 2003·International Journal of Behavioral Medicine·Yrsa Andersen HundrupJohn Philip
Aug 30, 2000·Ugeskrift for laeger·E F Eriksen
Jul 24, 2001·PharmacoEconomics·P VestergaardL Mosekilde
Dec 18, 2013·International Journal of Biological Sciences·Jin DaiZhousheng Xiao
Mar 30, 2007·Pharmacogenomics·José A Riancho
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·J AnD C Leitman
Jul 27, 2001·Current Treatment Options in Gastroenterology·Ad A. van BodegravenStephan G. M. Meuwissen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.